aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025

aTYR PHARMA INC

Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.
Cash, equivalents and investments were $83.2M at June 30, 2025; raised ~$30.7M from ATM offering post-quarter.
R&D expenses $15.4M, G&A $4.9M for Q2 2025.
Interim Phase 2 EFZO-CONNECT data in SSc-ILD showed stable/improved mRSS in efzofitimod-treated patients (n=8).
Advanced ATYR0101 to IND candidate for pulmonary fibrosis; IND filing expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.